Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma

This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study. The study follow-up duration will be five years. The primary outcome is the composite of incident high-risk varices, hepatic decompensation and liver-related mortality. The participants will undergo transient elastography at baseline and then half-yearly post-HCC curative treatment; and oesophagogastroduodenoscopy (OGD) at baseline and then at year 1, 3 and 5 post-HCC curative treatment. Clinical assessments and laboratory tests will also be done at baseline and every 6 months until year 5 to identify any clinical events.

NCT Number	NCT07036874
Lead Sponsor	Chinese University of Hong Kong
Conditions	HCC - Hepatocellular Carcinoma, Cirrhosis
Enrollment	159 participants
Start Date	2024-11-04
Primary Completion	2030-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2025-06-29